An engineered IN-1 F(ab) fragment with improved affinity for the Nogo-A axonal growth inhibitor permits immunochemical detection and shows enhanced neutralizing activity - PubMed (original) (raw)

An engineered IN-1 F(ab) fragment with improved affinity for the Nogo-A axonal growth inhibitor permits immunochemical detection and shows enhanced neutralizing activity

M Fiedler et al. Protein Eng. 2002 Nov.

Abstract

The myelin axonal growth inhibitor NI-220/250 (Nogo-A) has attracted considerable attention in elucidating the mechanisms that account for the lack of plasticity in the adult central nervous system. The cognate monoclonal antibody IN-1, which was obtained prior to the molecular characterization of its Nogo-A antigen, has played a crucial role in this respect. However, this murine IgM/kappa antibody does not only provide an inappropriate format for in vivo studies, its low antigen affinity has also hampered the thorough structure-function analysis of its neutralizing effect toward the Nogo-A inhibitor on a molecular basis. We describe here the affinity maturation of a bacterially produced functional IN-1 F(ab) fragment via protein engineering. A soluble fragment of Nogo-A derived from the central exon 3 of its gene, which was prepared by secretion into the periplasm of Escherichia coli, served as a target in these experiments. After repeated cycles of site-directed random mutagenesis and screening, the mutant II.1.8 of the IN-1 F(ab) fragment was obtained, carrying five side chain substitutions within CDR-L3. Its dissociation constant for the complex with the recombinant Nogo-A fragment was determined in surface plasmon resonance measurements as approximately 1 microM. The affinity of the unmutated IN-1 F(ab) fragment was 8-fold lower. The engineered F(ab) fragment appeared to be well suited for the specific detection of Nogo-A in immunochemical assays and for the histochemical staining of myelin-rich tissue sections. Most importantly, its concentration-dependent neutralizing effect on the Nogo-A inhibitory activity was significantly enhanced in cell culture. This study confirms Nogo-A to be the antigen of the IN-1 antibody and it demonstrates increased potential of the engineered F(ab) fragment as a reagent for promoting axonal regeneration in vivo.

PubMed Disclaimer

Cited by

Understanding and Modulating Antibody Fine Specificity: Lessons from Combinatorial Biology.
Rojas G. Rojas G. Antibodies (Basel). 2022 Jul 14;11(3):48. doi: 10.3390/antib11030048. Antibodies (Basel). 2022. PMID: 35892708 Free PMC article. Review.
Improvement of antibody affinity by introduction of basic amino acid residues into the framework region.
Fukunaga A, Maeta S, Reema B, Nakakido M, Tsumoto K. Fukunaga A, et al. Biochem Biophys Rep. 2018 Jul 14;15:81-85. doi: 10.1016/j.bbrep.2018.07.005. eCollection 2018 Sep. Biochem Biophys Rep. 2018. PMID: 30073208 Free PMC article.
Translational spinal cord injury research: preclinical guidelines and challenges.
Reier PJ, Lane MA, Hall ED, Teng YD, Howland DR. Reier PJ, et al. Handb Clin Neurol. 2012;109:411-33. doi: 10.1016/B978-0-444-52137-8.00026-7. Handb Clin Neurol. 2012. PMID: 23098728 Free PMC article. Review.
Prominin-1 localizes to the open rims of outer segment lamellae in Xenopus laevis rod and cone photoreceptors.
Han Z, Anderson DW, Papermaster DS. Han Z, et al. Invest Ophthalmol Vis Sci. 2012 Jan 25;53(1):361-73. doi: 10.1167/iovs.11-8635. Invest Ophthalmol Vis Sci. 2012. PMID: 22076989 Free PMC article.
Aptamer antagonists of myelin-derived inhibitors promote axon growth.
Wang Y, Khaing ZZ, Li N, Hall B, Schmidt CE, Ellington AD. Wang Y, et al. PLoS One. 2010 Mar 16;5(3):e9726. doi: 10.1371/journal.pone.0009726. PLoS One. 2010. PMID: 20300533 Free PMC article.

An engineered IN-1 F(ab) fragment with improved affinity for the Nogo-A axonal growth inhibitor permits immunochemical detection and shows enhanced neutralizing activity - PubMed (original) (raw)